These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37032288)

  • 1. Evaluation of T-Cell Immune Status of Reduced-Dose Cyclosporine and Everolimus Combination Therapy in Kidney Transplant Patients.
    Tanaka A; Ide K; Tanaka Y; Sasaki Y; Doskali M; Tahara H; Ohira M; Ohdan H
    Transplant Proc; 2023 May; 55(4):797-802. PubMed ID: 37032288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-year follow-up of a randomized clinical study comparing everolimus plus reduced-dose cyclosporine with mycophenolate mofetil plus standard-dose cyclosporine in de novo kidney transplantation: Retrospective single center assessment.
    Hiramitsu T; Okada M; Futamura K; Yamamoto T; Tsujita M; Goto N; Narumi S; Watarai Y; Takeda A; Iwasaki K; Uchida K; Kobayashi T
    Int Immunopharmacol; 2016 Oct; 39():192-198. PubMed ID: 27491025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of everolimus-based drug regimens on CMV-specific T-cell functionality after renal transplantation: 12-month ATHENA subcohort-study results.
    Hauser IA; Marx S; Sommerer C; Suwelack B; Dragun D; Witzke O; Lehner F; Schiedel C; Porstner M; Thaiss F; Neudörfl C; Falk CS; Nashan B; Sester M
    Eur J Immunol; 2021 Apr; 51(4):943-955. PubMed ID: 33306229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.
    Pascual J; Berger SP; Witzke O; Tedesco H; Mulgaonkar S; Qazi Y; Chadban S; Oppenheimer F; Sommerer C; Oberbauer R; Watarai Y; Legendre C; Citterio F; Henry M; Srinivas TR; Luo WL; Marti A; Bernhardt P; Vincenti F;
    J Am Soc Nephrol; 2018 Jul; 29(7):1979-1991. PubMed ID: 29752413
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of everolimus plus low-dose calcineurin inhibitor vs. mycophenolate mofetil plus standard-dose calcineurin inhibitor in renal transplant recipients: A systematic review and meta-analysis
.
    He L; Deng J; Yang B; Jiang W
    Clin Nephrol; 2018 May; 89(5):336-344. PubMed ID: 29292693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steroid Withdrawal Using Everolimus in ABO-Incompatible Kidney Transplant Recipients With Post-Transplant Diabetes Mellitus.
    Nanmoku K; Shinzato T; Kubo T; Shimizu T; Kimura T; Yagisawa T
    Transplant Proc; 2018 May; 50(4):1050-1055. PubMed ID: 29631750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.
    Berger SP; Sommerer C; Witzke O; Tedesco H; Chadban S; Mulgaonkar S; Qazi Y; de Fijter JW; Oppenheimer F; Cruzado JM; Watarai Y; Massari P; Legendre C; Citterio F; Henry M; Srinivas TR; Vincenti F; Gutierrez MPH; Marti AM; Bernhardt P; Pascual J;
    Am J Transplant; 2019 Nov; 19(11):3018-3034. PubMed ID: 31152476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adequacy of Initial Everolimus Dose, With and Without Calcineurin Inhibitors, in Kidney Transplant Recipients.
    Felipe C; Ferreira A; Bessa A; Abait T; Perez JD; Casarini DE; Medina-Pestana J; Tedesco H
    Ther Drug Monit; 2018 Feb; 40(1):52-58. PubMed ID: 29271815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
    Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
    Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion to Everolimus in Kidney Transplant Recipients With Calcineurin Inhibitor-Induced Nephropathy: 3 Case Reports.
    Nanmoku K; Shinzato T; Kubo T; Shimizu T; Yagisawa T
    Transplant Proc; 2019 Jun; 51(5):1424-1427. PubMed ID: 31060742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concentration-controlled everolimus (Certican): combination with reduced dose calcineurin inhibitors.
    Pascual J
    Transplantation; 2005 May; 79(9 Suppl):S76-9. PubMed ID: 15880020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.
    Uchida J; Machida Y; Iwai T; Kuwabara N; Kabei K; Naganuma T; Kumada N; Kawashima H; Nakatani T
    Clin Transplant; 2014 Jan; 28(1):80-7. PubMed ID: 24329776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing the immunosuppressive regimen in heart transplantation.
    Eisen H; Ross H
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppression Modification by Everolimus With Minimization of Calcineurin Inhibitors Recovers Kidney Graft Function Even in Patients With Very Late Conversion and Also With Poor Graft Function.
    Nojima M; Yamada Y; Higuchi Y; Shimatani K; Kanematsu A; Yamamoto S
    Transplant Proc; 2017; 49(1):41-44. PubMed ID: 28104155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial.
    Budde K; Zeier M; Witzke O; Arns W; Lehner F; Guba M; Jacobi J; Kliem V; Reinke P; Hauser IA; Vogt B; Stahl R; Rath T; Duerr M; Paulus EM; May C; Porstner M; Sommerer C;
    Nephrol Dial Transplant; 2017 Jun; 32(6):1060-1070. PubMed ID: 28605781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus-facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2-year results from the subgroup analysis of the TRANSFORM study.
    Watarai Y; Danguilan R; Casasola C; Chang SS; Ruangkanchanasetr P; Kee T; Wong HS; Kenmochi T; Amante AJ; Shu KH; Ingsathit A; Bernhardt P; Hernandez-Gutierrez MP; Han DJ; Kim MS
    Clin Transplant; 2021 Oct; 35(10):e14415. PubMed ID: 34216395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors.
    Perbos E; Juinier E; Guidicelli G; Dromer C; Merville P; Billes MA; Taupin JL; Neau-Cransac M
    Clin Transplant; 2014 Sep; 28(9):1054-60. PubMed ID: 25040585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronopharmacokinetics of mycophenolic acid and its glucuronide and acyl glucuronide metabolites in kidney transplant recipients converted from cyclosporine to everolimus.
    Tedesco-Silva H; Felipe CR; Slade A; Schmouder RL; Medina Pestana JO
    Ther Drug Monit; 2012 Dec; 34(6):652-9. PubMed ID: 23131696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.
    Tedesco-Silva H; Felipe C; Ferreira A; Cristelli M; Oliveira N; Sandes-Freitas T; Aguiar W; Campos E; Gerbase-DeLima M; Franco M; Medina-Pestana J
    Am J Transplant; 2015 Oct; 15(10):2655-64. PubMed ID: 25988935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.